Re-irradiation for recurrent esophageal cancer: clinical benefit, survival outcomes, and toxicity profile
Palliative reirradiation in patients with recurrent esophageal cancer showed clinical benefit in 72% of the patients, with impact on OS both in M0 and M1 patients and low rate of acute toxicity. These findings support the use of reirradiation as a feasible and effective strategy in selected patients with recurrent esophageal cancer.
Authors
- Chiara Mattioli (ORCID: https://orcid.org/0000-0002-1584-1991)
- M. Loi (ORCID: https://orcid.org/0009-0009-3443-197X)
- Lucy A. van Werkhoven (ORCID: https://orcid.org/0009-0000-3865-5692)
- Joost J. Nuyttens (ORCID: https://orcid.org/0009-0002-5021-1597)
Institutions
- Azienda Ospedaliero-Universitaria Careggi (IT)
- Erasmus MC Cancer Institute (NL)
Publication Details
- Journal
- Clinical and Translational Radiation Oncology
- Published
- 2025-11-05
- DOI
- https://doi.org/10.1016/j.ctro.2025.101068
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00